Trial phases describe the stage and main questions of a human drug study. Phase 1 explores early safety, phase 2 looks for signs of benefit and further safety information, and phase 3 tests benefits and risks in larger groups. A phase 3 trial does not mean the product is FDA-approved.
When you see a peptide described as “in phase 2” or “entering phase 3,” use the number to understand where the research stands. Then look for what the study actually found.
1. What does each phase ask?
Before human trials, researchers study a potential medicine in laboratory and animal work. That is preclinical research. It helps researchers decide whether human testing can begin; it cannot establish how well a treatment works in people.
| Stage | Main question |
|---|---|
| Phase 1 | How does the drug behave in the body, and what early side effects appear? |
| Phase 2 | Does it show signs of helping people with the condition, and what further safety information emerges? |
| Phase 3 | Do larger studies support a treatment benefit, and how do benefits and adverse effects compare with the study’s control group? |
| Phase 4 | After approval, what more can we learn about the medicine’s benefits and risks? |
This follows FDA’s explanation of clinical research. Study sizes and lengths vary. The phases describe a typical development path, not an automatic progression: a study can raise questions that require more work.
2. What does a phase number leave out?
“Phase 3” gives you a stage. To judge a claim, you also need the study’s design and results. Open the linked paper or study record and ask:
- Who took part? Note the condition, age group, number of participants, and length of follow-up.
- What was tested? Find the exact product, including whether it was one compound or a combination.
- What was the comparison? A placebo, another treatment, and no comparison group provide different kinds of information.
- What was measured? Look for the main outcome chosen in advance, alongside side effects and treatment withdrawals.
- Are results available? “Recruiting” describes enrollment. “Completed” describes study status; neither word tells you whether the treatment worked.
For example, a change in a blood test and fewer hospital stays are different outcomes. A surrogate endpoint is an indirect measure used to stand in for a health outcome. Ask whether that measure reliably predicts the health benefit being claimed. FDA’s research definitions explain that distinction.
PeptideWhy’s source method explains how we separate human trials, animal research, and other reports.
3. Where does FDA approval fit?
In the United States, investigating a new drug and obtaining permission to market it are separate steps. The Investigational New Drug application, or IND, supports the clinical investigation. A marketing application asks FDA to evaluate the product for a proposed use.
FDA reviews the evidence, proposed labeling, and manufacturing information. It considers whether benefits outweigh risks for the intended use and whether the product can be made consistently. The agency may ask for explanations or additional studies. FDA’s drug-review overview describes that process.
So “positive phase 3 results,” “application submitted,” and “under FDA review” describe different milestones. None alone says approval has been granted. Check the actual approval and the use it covers. For the separate question of labels on online vials, see what research use only means.
4. Why do studies continue after approval?
Approval does not mean researchers have learned everything about a medicine. Some problems become clearer with longer follow-up or wider use. Phase 4 studies and other safety monitoring help build that picture; FDA can update warnings when new information warrants it. See FDA’s post-market monitoring explanation.
An approved medicine can also be investigated for a new condition or a different form. Read the phase number together with the study’s purpose and the product’s existing approval, rather than assigning one permanent research stage to a molecule.
Try it: open a profile in the peptide library, follow one human-study link, and identify its participants, comparison, main outcome, and results. Those details make the phase number useful.